Research progress on heterotopic gastric mucosa in the esophagus_West China Medical Journal

Authors：

XIONG Xin ¹ , CHEN Yuan ¹ , LI Shuyi ¹ , XU Zhihong ¹ , ZHANG Xiumei ¹ , TANG Shilin ¹ , GUO Hao ² , HUANG Ping ² ,  HE Suyu ¹

1. Department of Gastroenterology, Suining Central Hospital, Suining, Sichuan 629000, P. R. China;
2. School of Clinical Medicine, North Sichuan Medical College, Nanchong, Sichuan 637000, P. R. China;

Corresponding?author：

HE Suyu, Email: hesuyu2009@163.com

Keywords：

Heterotopic gastric mucosa in the esophagus; heterotopic gastric mucosa in the upper esophagu; Barrett esophagus; gastroesophageal reflux disease; esophageal adenocarcinoma

DOI：

10.7507/1002-0179.202508044

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Heterotopic gastric mucosa in the esophagus (HGME) refers to the heterotopic distribution of gastric mucosa in the esophagus. Its subtypes include heterotopic gastric mucosa in the upper esophagus, heterotopic gastric mucosa in the middle esophagus and Barrett esophagus. To date, the occurrence, development and clinical characteristics of each subtype are closely related to gastroesophageal reflux disease, but there are few reviews elaborating on their similarities and differences. This report analyzes the commonalities and differences of HGME subtypes from multiple perspectives including pathogenesis, epidemiology, high-risk factors, clinical symptoms, auxiliary examinations, treatment and prognosis, aiming to provide guidance for future research and clinical practice.

Citation： XIONG Xin, CHEN Yuan, LI Shuyi, XU Zhihong, ZHANG Xiumei, TANG Shilin, GUO Hao, HUANG Ping, HE Suyu. Research progress on heterotopic gastric mucosa in the esophagus. West China Medical Journal, 2026, 41(7): 1187-1195. doi: 10.7507/1002-0179.202508044 Copy

1.	Thompson R, Glogowski S, Ghazi A, et al. Heterotopic gastric mucosa and intestinal atresia in a neonate[J]. Proc (Bayl Univ Med Cent), 2021, 34(3): 369-370.
2.	Rusu R, Ishaq S, Wong T, et al. Cervical inlet patch: new insights into diagnosis and endoscopic therapy[J]. Frontline Gastroenterol, 2018, 9(3): 214-220.
3.	Cock C, Hamarneh Z. Gastric inlet patches: symptomatic or silent?[J]. Curr Opin Otolaryngol Head Neck Surg, 2019, 27(6): 453-462.
4.	Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study[J]. Gut, 2008, 57(10): 1354-1359.
5.	Weinstock MS, Simons JP, Dohar JE. Heterotopic gastric mucosa of the proximal esophageal (HGMPE) and its potential role in pediatric dysphonia and dysphagia[J]. Int J Pediatr Otorhinolaryngol, 2020, 138: 110271.
6.	Groulx S, Limburg H, Doull M, et al. Guideline on screening for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease[J]. CMAJ, 2020, 192(27): E768-E777.
7.	Kishimoto K, Shibagaki K, Nonomura S, et al. Heterotopic gastric mucosa in middle esophagus complicated with esophageal ulcers[J]. Intern Med, 2022, 61(18): 2735-2740.
8.	陳怡, 李明. 食管中段胃黏膜異位合并憩室形成 1 例并臨床病理分析[J]. 武警后勤學院學報, 2020, 29(5): 72-74.
9.	Georges A, Coopman S, Rebeuh J, et al. Inlet patch: clinical presentation and outcome in children[J]. J Pediatr Gastroenterol Nutr, 2011, 52(4): 419-423.
10.	Xiong X, He S, Xu F, et al. Gastroesophageal reflux disease and salivary pepsin in patients with heterotopic gastric mucosa in the upper esophagus[J]. Dis Esophagus, 2022, 35(4): doab074.
11.	Deboever N, Jones CM, Yamashita K, et al. Advances in diagnosis and management of cancer of the esophagus[J]. BMJ, 2024, 385: e074962.
12.	Lauwers GY, Mino M, Ban S, et al. Cytokeratins 7 and 20 and mucin core protein expression in esophageal cervical inlet patch[J]. Am J Surg Pathol, 2005, 29(4): 437-442.
13.	Feurle GE, Helmstaedter V, Buehring A, et al. Distinct immunohistochemical findings in columnar epithelium of esophageal inlet patch and of Barrett’s esophagus[J]. Dig Dis Sci, 1990, 35(1): 86-92.
14.	王振翔, 陳瑩, 孫會會, 等. 食管上段胃黏膜異位與咽喉反流[J]. 中華消化內鏡雜志, 2021, 38(4): 329-333.
15.	Yin Y, Li H, Feng J, et al. Prevalence and clinical and endoscopic characteristics of cervical inlet patch (heterotopic gastric mucosa): a systematic review and meta-analysis[J]. J Clin Gastroenterol, 2022, 56(3): e250-e262.
16.	Akar T, Ayd?n S. The true prevalence of cervical inlet patch in a specific center dealing with esophageal diseases[J]. Eur Rev Med Pharmacol Sci, 2022, 26(9): 3127-3131.
17.	Romańczyk M, Romańczyk T, Lesińska M, et al. Influence of narrow-band imaging (NBI) and enhanced operator’s attention during esophagus inspection on cervical inlet patches detection[J]. Adv Med Sci, 2021, 66(1): 170-175.
18.	Sharma P. Barrett esophagus: a review[J]. JAMA, 2022, 328(7): 663-671.
19.	Marques de Sá I, Marcos P, Sharma P, et al. The global prevalence of Barrett’s esophagus: a systematic review of the published literature[J]. United European Gastroenterol J, 2020, 8(9): 1086-1105.
20.	Shiota S, Singh S, Anshasi A, et al. Prevalence of Barrett’s esophagus in Asian countries: a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2015, 13(11): 1907-1918.
21.	Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study[J]. Gastroenterology, 2005, 129(6): 1825-1831.
22.	Marques de Sá I, Leal C, Silva J, et al. Prevalence of Barrett’s esophagus in a Southern European country: a multicenter study[J]. Eur J Gastroenterol Hepatol, 2021, 33(1S Suppl 1): e939-e943.
23.	Alsahafi M, Mimish H, Salem F, et al. The prevalence of Barrett’s esophagus among a Saudi Arabian population[J]. Dig Dis Sci, 2021, 66(7): 2311-2316.
24.	Masri O, Ibrahim F, Badreddine R, et al. Prevalence of Barrett’s esophagus in Lebanon[J]. Turk J Gastroenterol, 2015, 26(3): 214-217.
25.	Rashidian M, Bastan F, Soltani H, et al. The prevalence of Barrett’s esophagus in Iranian patients with gastrointestinal symptoms: a systematic review and meta-analysis[J]. BMC Gastroenterol, 2025, 25(1): 217.
26.	Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett’s esophagus: a population-based study[J]. Am J Gastroenterol, 2011, 106(8): 1447-1455.
27.	Dhaliwal L, Kamboj AK, Williams JL, et al. Prevalence and predictors of Barrett’s esophagus after negative initial endoscopy: analysis from two national databases[J]. Clin Gastroenterol Hepatol, 2024, 22(3): 523-531.e3.
28.	Ebigbo A, Messmann H, Lee SH. Artificial intelligence applications in image-based diagnosis of early esophageal and gastric neoplasms[J]. Gastroenterology, 2025, 169(3): 396-415.e2.
29.	王靜, 平付敏, 朱慶華, 等. 食管上段胃黏膜異位的發病率及危險因素研究[J]. 河北醫藥, 2019, 41(14): 2161-2164.
30.	Govani SM, Metko V, Rubenstein JH. Prevalence and risk factors for heterotopic gastric mucosa of the upper esophagus among men undergoing routine screening colonoscopy[J]. Dis Esophagus, 2015, 28(5): 442-447.
31.	吐爾遜阿依·熱夏提, 高峰. 食管上段異位胃黏膜危險因素的研究[J]. 胃腸病學, 2020, 11(6): 339-343.
32.	Avidan B, Sonnenberg A, Chejfec G, et al. Is there a link between cervical inlet patch and Barrett’s esophagus?[J]. Gastrointest Endosc, 2001, 53(7): 717-721.
33.	Clermont M, Falk GW. Clinical guidelines update on the diagnosis and management of Barrett’s esophagus[J]. Dig Dis Sci, 2018, 63(8): 2122-2128.
34.	Zhao Z, Yin Z, Zhang C. Lifestyle interventions can reduce the risk of Barrett’s esophagus: a systematic review and meta-analysis of 62 studies involving 250,157 participants[J]. Cancer Med, 2021, 10(15): 5297-5320.
35.	Karimian M, Salamati M, Azami M. The relationship between metabolic syndrome and increased risk of Barrett’s esophagus: an updated systematic review and meta-analysis[J]. BMC Gastroenterol, 2020, 20(1): 138.
36.	Liu BD, Udemba SC, Saleh S, et al. Raloxifene increases the risk of gastroesophageal reflux disease, Barrett’s esophagus, and esophageal stricture in postmenopausal women with osteoporosis[J]. Neurogastroenterol Motil, 2023, 35(12): e14689.
37.	Huang Y, Cai Y, Chen Y, et al. Cholelithiasis and cholecystectomy increase the risk of gastroesophageal reflux disease and Barrett’s esophagus[J]. Front Med (Lausanne), 2024, 11: 1420462.
38.	Ma S, Tong Z, He Y, et al. Association between hiatal hernia and Barrett’s esophagus: an updated meta-analysis with trial sequential analysis[J]. Therap Adv Gastroenterol, 2024, 17: 17562848231219234.
39.	Iwaya Y, Goda K, Kako S, et al. Association between endoscopic evidence of bile reflux and Barrett’s esophagus: a large-scale case-control study[J]. Dig Liver Dis, 2024, 56(4): 622-627.
40.	Liu Q, Liu X, Gao M, et al. Investigation of causal associations between cerebral cortical structure and Barrett’s esophagus: insights from Mendelian randomization and meta-analysis[J]. J Thorac Dis, 2024, 16(12): 8582-8601.
41.	Edelstein ZR, Bronner MP, Rosen SN, et al. Risk factors for Barrett’s esophagus among patients with gastroesophageal reflux disease: a community clinic-based case-control study[J]. Am J Gastroenterol, 2009, 104(4): 834-842.
42.	Eusebi LH, Telese A, Cirota GG, et al. Systematic review with meta-analysis: risk factors for Barrett’s oesophagus in individuals with gastro-oesophageal reflux symptoms[J]. Aliment Pharmacol Ther, 2021, 53(9): 968-976.
43.	Zhang J, Wu H, Wang R. Effect of nonsteroidal anti-inflammatory drugs on Barrett’s esophagus risk: a systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2021, 45(3): 101552.
44.	Zhang X, Yang X, Zhang T, et al. Association of educational attainment with esophageal cancer, Barrett’s esophagus, and gastroesophageal reflux disease, and the mediating role of modifiable risk factors: a Mendelian randomization study[J]. Front Public Health, 2023, 11: 1022367.
45.	Zhou J, Fang P, Liu Y, et al. Causal relationship between cheese intake and risk of gastroesophageal reflux disease and Barrett’s esophagus: findings from multivariable mendelian randomization and mediation analysis[J]. Eur J Nutr, 2024, 64(1): 49.
46.	中國醫療保健國際交流促進會胃食管反流病學分會. 中國胃食管反流病多學科診療共識 2022(一)[J]. 中華胃食管反流病電子雜志, 2022, 9(2): 51-86.
47.	von Rahden BH, Stein HJ, Becker K, et al. Heterotopic gastric mucosa of the esophagus: literature-review and proposal of a clinicopathologic classification[J]. Am J Gastroenterol, 2004, 99(3): 543-551.
48.	Chong VH, Jalihal A. Heterotopic gastric mucosal patch of the esophagus is associated with higher prevalence of laryngopharyngeal reflux symptoms[J]. Eur Arch Otorhinolaryngol, 2010, 267(11): 1793-1799.
49.	Yu X, Wang J, Jin T, et al. Laryngopharyngeal symptoms and oesophageal disorder: the role of heterotopic gastric mucosa in upper oesophagus[J]. Clin Otolaryngol, 2023, 48(1): 32-38.
50.	Chen X, Zhou S, Shi C, et al. Association of heterotopic gastric mucosa in the upper esophagus (HGMUE) with pharyngolaryngeal symptoms: a systematic review and meta-analysis[J]. Dig Dis Sci, 2024, 69(12): 4416-4429.
51.	Romańczyk M, Budzyń K, Romańczyk T, et al. Heterotopic gastric mucosa in the proximal esophagus: prospective study and systematic review on relationships with endoscopic findings and clinical data[J]. Dysphagia, 2023, 38(2): 629-640.
52.	吳瑞暖, 劉朝暉. 食管胃黏膜異位病理診斷分型與臨床癥狀的關系[J]. 海南醫學, 2020, 10(11): 1377-1379.
53.	Wang Z, Chen Y, Sun H, et al. Risk factors for symptoms in patients with heterotopic gastric mucosa in the upper esophagus[J]. Gastroenterol Res Pract, 2025, 2025: 7658517.
54.	Bognár L, Vereczkei A, Papp A, et al. Gastroesophageal reflux disease might induce certain-supposedly adaptive-changes in the esophagus: a hypothesis[J]. Dig Dis Sci, 2018, 63(10): 2529-2535.
55.	Iwaya Y, Shimamura Y, Goda K, et al. Clinical characteristics of young patients with early Barrett’s neoplasia[J]. World J Gastroenterol, 2019, 25(24): 3069-3078.
56.	Quach DT, Pham QTT, Tran TLT, et al. Prevalence, clinical characteristics, and risk factors of Barrett esophagus in Vietnamese patients with upper gastrointestinal symptoms[J]. Medicine (Baltimore), 2020, 99(34): e21791.
57.	Lechien JR, Saussez S, Muls V, et al. Laryngopharyngeal reflux: a state-of-the-art algorithm management for primary care physicians[J]. J Clin Med, 2020, 9(11): 3618.
58.	Nason KS, Murphy T, Schindler J, et al. A cross-sectional analysis of the prevalence of Barrett esophagus in otolaryngology patients with laryngeal symptoms[J]. J Clin Gastroenterol, 2013, 47(9): 762-768.
59.	Taylor JB, Rubenstein JH. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett’s esophagus[J]. Am J Gastroenterol, 2010, 105(8): 1729, 1730-1737, quiz 1738.
60.	Eusebi LH, Telese A, Cirota GG, et al. Effect of gastro-esophageal reflux symptoms on the risk of Barrett’s esophagus: a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2022, 37(8): 1507-1516.
61.	Borhan-Manesh F, Farnum JB. Incidence of heterotopic gastric mucosa in the upper oesophagus[J]. Gut, 1991, 32(9): 968-972.
62.	熊鑫, 何素玉, 徐菲, 等. 食管上段胃黏膜異位內鏡下合并癥的研究[J]. 中國內鏡雜志, 2021, 27(4): 1-6.
63.	ASGE Standards of Practice Committee, Qumseya B, Sultan S, et al. ASGE guideline on screening and surveillance of Barrett’s esophagus[J]. Gastrointest Endosc, 2019, 90(3): 335-359.
64.	Weusten BLAM, Bisschops R, Dinis-Ribeiro M, et al. Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline[J]. Endoscopy, 2023, 55(12): 1124-1146.
65.	Khatri R, Patel J, Song J, et al. Esophageal inlet patch: association with Barrett’s esophagus[J]. Dig Dis Sci, 2023, 68(9): 3671-3678.
66.	Frieling T, Kuhlbusch-Zicklam R, Weingardt C, et al. Clinical impact of esophageal function tests and argon plasma coagulation in heterotopic gastric mucosa of the esophagus and extraesophageal reflux symptoms - a prospective study[J]. Z Gastroenterol, 2015, 53(2): 101-107.
67.	Rosztóczy A, Izbéki F, Németh IB, et al. Detailed esophageal function and morphological analysis shows high prevalence of gastroesophageal reflux disease and Barrett’s esophagus in patients with cervical inlet patch[J]. Dis Esophagus, 2012, 25(6): 498-504.
68.	Korkut E, Bekta? M, Alkan M, et al. Esophageal motility and 24-h pH profiles of patients with heterotopic gastric mucosa in the cervical esophagus[J]. Eur J Intern Med, 2010, 21(1): 21-24.
69.	Coenraad M, Masclee AA, Straathof JW, et al. Is Barrett’s esophagus characterized by more pronounced acid reflux than severe esophagitis?[J]. Am J Gastroenterol, 1998, 93(7): 1068-1072.
70.	Iwakiri K, Sugiura T, Hayashi Y, et al. Esophageal motility in Japanese patients with Barrett’s esophagus[J]. J Gastroenterol, 2003, 38(11): 1036-1041.
71.	Bazin C, Benezech A, Alessandrini M, et al. Esophageal motor disorders are a strong and independant associated factor of Barrett’s esophagus[J]. J Neurogastroenterol Motil, 2018, 24(2): 216-225.
72.	Alonso O, Hernández D, Moreno E, et al. The real value of lower esophageal sphincter measurement for predicting acid gastroesophageal reflux or Barrett’s esophagus[J]. J Gastrointest Surg, 2005, 9(7): 973-979.
73.	Fass R, Teramoto O, Kurin M, et al. Esophageal function abnormalities in patients with Barrett’s esophagus[J]. J Clin Gastroenterol, 2020, 54(6): 485-492.
74.	Gutschow CA, Bludau M, Vallb?hmer D, et al. NERD, GERD, and Barrett’s esophagus: role of acid and non-acid reflux revisited with combined pH-impedance monitoring[J]. Dig Dis Sci, 2008, 53(12): 3076-3081.
75.	Tian Y, Zhang W, Zhang T, et al. Analysis of the correlation between dynamic characteristics and symptoms of gastroesophageal reflux disease[J]. Surg Laparosc Endosc Percutan Tech, 2024, 34(3): 268-274.
76.	Meneghetti AT, Tedesco P, Damani T, et al. Esophageal mucosal damage may promote dysmotility and worsen esophageal acid exposure[J]. J Gastrointest Surg, 2005, 9(9): 1313-1317.
77.	Cho YK. Length of the Barrett’s esophagus is proportional to the abnormality of esophageal motility and anti-reflux barrier[J]. J Neurogastroenterol Motil, 2023, 29(1): 5-6.
78.	Falc?o A, Nasi A, Brand?o J, et al. What is the real impairment on esophageal motility in patients with gastroesophageal reflux disease?[J]. Arq Gastroenterol, 2013, 50(2): 111-116.
79.	Shibli F, Fass OZ, Teramoto OM, et al. Esophageal hypocontractile disorders and hiatal hernia size are predictors for long segment Barrett’s esophagus[J]. J Neurogastroenterol Motil, 2023, 29(1): 31-37.
80.	Oberg S, DeMeester TR, Peters JH, et al. The extent of Barrett’s esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure[J]. J Thorac Cardiovasc Surg, 1999, 117(3): 572-580.
81.	Lidums I, Holloway R. Motility abnormalities in the columnar-lined esophagus[J]. Gastroenterol Clin North Am, 1997, 26(3): 519-531.
82.	Yadlapati R, Triggs J, Quader F, et al. Reduced esophageal contractility is associated with dysplasia progression in Barrett’s esophagus: a multicenter cohort study[J]. Dig Dis Sci, 2020, 65(12): 3631-3638.
83.	Mason RJ, Bremner CC. Motility differences between long-segment and short-segment Barrett’s esophagus[J]. Am J Surg, 1993, 165(6): 686-689.
84.	Falc?o AM, Nasi A, Szachnowicz S, et al. Does the nissen fundoplication procedure improve esophageal dysmotility in patients with Barrett’s esophagus[J]. Rev Col Bras Cir, 2020, 47: e20202637.
85.	Philonenko S, Roman S, Zerbib F, et al. Jackhammer esophagus: clinical presentation, manometric diagnosis, and therapeutic results-Results from a multicenter French cohort[J]. Neurogastroenterol Motil, 2020, 32(11): e13918.
86.	Dao HV, Hoang LB, Luu MT, et al. High prevalence of esophagitis in patients with severe ineffective esophageal motility: need for a new diagnostic cutoff[J]. Ann Gastroenterol, 2022, 35(5): 483-488.
87.	Guo JP, Gilman PB, Thomas RM, et al. Barrett’s esophagus and achalasia[J]. J Clin Gastroenterol, 2002, 34(4): 439-443.
88.	Leeuwenburgh I, Scholten P, Caljé TJ, et al. Barrett’s esophagus and esophageal adenocarcinoma are common after treatment for achalasia[J]. Dig Dis Sci, 2012, 58(1): 244-252.
89.	Yadlapati R, Kahrilas PJ, Fox MR, et al. Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0?[J]. Neurogastroenterol Motil, 2021, 33(1): e14058.
90.	Hamilton JW, Thune RG, Morrissey JF. Symptomatic ectopic gastric epithelium of the cervical esophagus. Demonstration of acid production with Congo red[J]. Dig Dis Sci, 1986, 31(4): 337-342.
91.	Loughney T, Maydonovitch CL, Wong RK. Esophageal manometry and ambulatory 24-hour pH monitoring in patients with short and long segment Barrett’s esophagus[J]. Am J Gastroenterol, 1998, 93(6): 916-919.
92.	Csendes A, Smok G, Quiroz J, et al. Clinical, endoscopic, and functional studies in 408 patients with Barrett’s esophagus, compared to 174 cases of intestinal metaplasia of the cardia[J]. Am J Gastroenterol, 2002, 97(3): 554-560.
93.	Gillen P, Keeling P, Byrne PJ, et al. Barrett’s oesophagus: pH profile[J]. Br J Surg, 1987, 74(9): 774-776.
94.	Shapiro M, Green C, Faybush EM, et al. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups[J]. Aliment Pharmacol Ther, 2006, 23(2): 321-329.
95.	Dickman R, Bautista JM, Wong WM, et al. Comparison of esophageal acid exposure distribution along the esophagus among the different gastroesophageal reflux disease (GERD) groups[J]. Am J Gastroenterol, 2006, 101(11): 2463-2469.
96.	Savarino E, Zentilin P, Frazzoni M, et al. Characteristics of gastro-esophageal reflux episodes in Barrett’s esophagus, erosive esophagitis and healthy volunteers[J]. Neurogastroenterol Motil, 2010, 22(10): 1061-e280.
97.	Basnayake C, Geeraerts A, Pauwels A, et al. Systematic review: duodenogastroesophageal (biliary) reflux prevalence, symptoms, oesophageal lesions and treatment[J]. Aliment Pharmacol Ther, 2021, 54(6): 755-778.
98.	Stein HJ, Kauer WK, Feussner H, et al. Bile reflux in benign and malignant Barrett’s esophagus: effect of medical acid suppression and nissen fundoplication[J]. J Gastrointest Surg, 1998, 2(4): 333-341.
99.	Ciocalteu A, Popa P, Ionescu M, et al. Issues and controversies in esophageal inlet patch[J]. World J Gastroenterol, 2019, 25(30): 4061-4073.
100.	Yamada T, Tsuji A, Onoue S, et al. Acid suppressive therapy improved symptoms due to circumferential cervical inlet patch with proton pumps (H⁺/K⁺-ATPase)[J]. World J Clin Cases, 2017, 5(11): 403-406.
101.	Sharma P, Shaheen NJ, Katzka D, et al. AGA clinical practice update on endoscopic treatment of Barrett’s esophagus with dysplasia and/or early cancer: expert review[J]. Gastroenterology, 2020, 158(3): 760-769.
102.	Chen Y, Sun C, Wu Y, et al. Do proton pump inhibitors prevent Barrett’s esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis[J]. J Cancer Res Clin Oncol, 2021, 147(9): 2681-2691.
103.	Zhuang Q, Chen S, Zhou X, et al. Comparative efficacy of P-CAB vs proton pump inhibitors for grade C/D esophagitis: a systematic review and network meta-analysis[J]. Am J Gastroenterol, 2024, 119(5): 803-813.
104.	Neumann WL, Luján GM, Genta RM et al. Gastric heterotopia in the proximal oesophagus (“inlet patch”): association with adenocarcinomas arising in Barrett mucosa[J]. Dig Liver Dis, 2012, 44(4): 292-206.
105.	Alagozlu H, Simsek Z, Unal S, et al. Is there an association between Helicobacter pylori in the inlet patch and globus sensation?[J]. World J Gastroenterol, 2010, 16(1): 42-47.
106.	Riddiough GE, Hornby ST, Asadi K, et al. Gastric adenocarinoma of the upper oesophagus: a literature review and case report[J]. Int J Surg Case Rep, 2017, 30(14): 205-214.
107.	Orosey M, Amin M, Cappell MS. A 14-year study of 398 esophageal adenocarcinomas diagnosed among 156, 256 EGDs performed at two large hospitals: an inlet patch is proposed as a significant risk factor for proximal esophageal adenocarcinoma[J]. Dig Dis Sci, 2018, 63(2): 452-465.
108.	Chong VH. Clinical significance of heterotopic gastric mucosal patch of the proximal esophagus[J]. World J Gastroenterol, 2013, 19(3): 331-338.
109.	Latos W, Sieroń-Sto?tny K, Kawczyk-Krupka A, et al. Clinical evaluation of twenty cases of heterotopic gastric mucosa of upper esophagus during five-year observation, using gastroscopy in combination with histopathological and microbiological analysis of biopsies[J]. Contemp Oncol, 2013, 17(2): 171-175.
110.	赫捷, 陳萬青, 李兆申, 等. 中國食管癌篩查與早診早治指南(2022, 北京)[J]. 中華腫瘤雜志, 2022, 44(6): 491-522.
111.	Uhlenhopp DJ, Then EO, Sunkara T, et al. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors[J]. Clin J Gastroenterol, 2020, 13(6): 1010-1021.
112.	Harrison M, Allen JE, Gorrepati VS, et al. Management of Barrett’s esophagus with low-grade dysplasia[J]. Dis Esophagus, 2018, 31(4): 101-109.
113.	Fabian T, Leung A. Epidemiology of Barrett’s esophagus and esophageal carcinoma[J]. Surg Clin North Am, 2021, 101(3): 381-389.

1. Thompson R, Glogowski S, Ghazi A, et al. Heterotopic gastric mucosa and intestinal atresia in a neonate[J]. Proc (Bayl Univ Med Cent), 2021, 34(3): 369-370.
2. Rusu R, Ishaq S, Wong T, et al. Cervical inlet patch: new insights into diagnosis and endoscopic therapy[J]. Frontline Gastroenterol, 2018, 9(3): 214-220.
3. Cock C, Hamarneh Z. Gastric inlet patches: symptomatic or silent?[J]. Curr Opin Otolaryngol Head Neck Surg, 2019, 27(6): 453-462.
4. Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study[J]. Gut, 2008, 57(10): 1354-1359.
5. Weinstock MS, Simons JP, Dohar JE. Heterotopic gastric mucosa of the proximal esophageal (HGMPE) and its potential role in pediatric dysphonia and dysphagia[J]. Int J Pediatr Otorhinolaryngol, 2020, 138: 110271.
6. Groulx S, Limburg H, Doull M, et al. Guideline on screening for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease[J]. CMAJ, 2020, 192(27): E768-E777.
7. Kishimoto K, Shibagaki K, Nonomura S, et al. Heterotopic gastric mucosa in middle esophagus complicated with esophageal ulcers[J]. Intern Med, 2022, 61(18): 2735-2740.
8. 陳怡, 李明. 食管中段胃黏膜異位合并憩室形成 1 例并臨床病理分析[J]. 武警后勤學院學報, 2020, 29(5): 72-74.
9. Georges A, Coopman S, Rebeuh J, et al. Inlet patch: clinical presentation and outcome in children[J]. J Pediatr Gastroenterol Nutr, 2011, 52(4): 419-423.
10. Xiong X, He S, Xu F, et al. Gastroesophageal reflux disease and salivary pepsin in patients with heterotopic gastric mucosa in the upper esophagus[J]. Dis Esophagus, 2022, 35(4): doab074.
11. Deboever N, Jones CM, Yamashita K, et al. Advances in diagnosis and management of cancer of the esophagus[J]. BMJ, 2024, 385: e074962.
12. Lauwers GY, Mino M, Ban S, et al. Cytokeratins 7 and 20 and mucin core protein expression in esophageal cervical inlet patch[J]. Am J Surg Pathol, 2005, 29(4): 437-442.
13. Feurle GE, Helmstaedter V, Buehring A, et al. Distinct immunohistochemical findings in columnar epithelium of esophageal inlet patch and of Barrett’s esophagus[J]. Dig Dis Sci, 1990, 35(1): 86-92.
14. 王振翔, 陳瑩, 孫會會, 等. 食管上段胃黏膜異位與咽喉反流[J]. 中華消化內鏡雜志, 2021, 38(4): 329-333.
15. Yin Y, Li H, Feng J, et al. Prevalence and clinical and endoscopic characteristics of cervical inlet patch (heterotopic gastric mucosa): a systematic review and meta-analysis[J]. J Clin Gastroenterol, 2022, 56(3): e250-e262.
16. Akar T, Ayd?n S. The true prevalence of cervical inlet patch in a specific center dealing with esophageal diseases[J]. Eur Rev Med Pharmacol Sci, 2022, 26(9): 3127-3131.
17. Romańczyk M, Romańczyk T, Lesińska M, et al. Influence of narrow-band imaging (NBI) and enhanced operator’s attention during esophagus inspection on cervical inlet patches detection[J]. Adv Med Sci, 2021, 66(1): 170-175.
18. Sharma P. Barrett esophagus: a review[J]. JAMA, 2022, 328(7): 663-671.
19. Marques de Sá I, Marcos P, Sharma P, et al. The global prevalence of Barrett’s esophagus: a systematic review of the published literature[J]. United European Gastroenterol J, 2020, 8(9): 1086-1105.
20. Shiota S, Singh S, Anshasi A, et al. Prevalence of Barrett’s esophagus in Asian countries: a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2015, 13(11): 1907-1918.
21. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study[J]. Gastroenterology, 2005, 129(6): 1825-1831.
22. Marques de Sá I, Leal C, Silva J, et al. Prevalence of Barrett’s esophagus in a Southern European country: a multicenter study[J]. Eur J Gastroenterol Hepatol, 2021, 33(1S Suppl 1): e939-e943.
23. Alsahafi M, Mimish H, Salem F, et al. The prevalence of Barrett’s esophagus among a Saudi Arabian population[J]. Dig Dis Sci, 2021, 66(7): 2311-2316.
24. Masri O, Ibrahim F, Badreddine R, et al. Prevalence of Barrett’s esophagus in Lebanon[J]. Turk J Gastroenterol, 2015, 26(3): 214-217.
25. Rashidian M, Bastan F, Soltani H, et al. The prevalence of Barrett’s esophagus in Iranian patients with gastrointestinal symptoms: a systematic review and meta-analysis[J]. BMC Gastroenterol, 2025, 25(1): 217.
26. Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett’s esophagus: a population-based study[J]. Am J Gastroenterol, 2011, 106(8): 1447-1455.
27. Dhaliwal L, Kamboj AK, Williams JL, et al. Prevalence and predictors of Barrett’s esophagus after negative initial endoscopy: analysis from two national databases[J]. Clin Gastroenterol Hepatol, 2024, 22(3): 523-531.e3.
28. Ebigbo A, Messmann H, Lee SH. Artificial intelligence applications in image-based diagnosis of early esophageal and gastric neoplasms[J]. Gastroenterology, 2025, 169(3): 396-415.e2.
29. 王靜, 平付敏, 朱慶華, 等. 食管上段胃黏膜異位的發病率及危險因素研究[J]. 河北醫藥, 2019, 41(14): 2161-2164.
30. Govani SM, Metko V, Rubenstein JH. Prevalence and risk factors for heterotopic gastric mucosa of the upper esophagus among men undergoing routine screening colonoscopy[J]. Dis Esophagus, 2015, 28(5): 442-447.
31. 吐爾遜阿依·熱夏提, 高峰. 食管上段異位胃黏膜危險因素的研究[J]. 胃腸病學, 2020, 11(6): 339-343.
32. Avidan B, Sonnenberg A, Chejfec G, et al. Is there a link between cervical inlet patch and Barrett’s esophagus?[J]. Gastrointest Endosc, 2001, 53(7): 717-721.
33. Clermont M, Falk GW. Clinical guidelines update on the diagnosis and management of Barrett’s esophagus[J]. Dig Dis Sci, 2018, 63(8): 2122-2128.
34. Zhao Z, Yin Z, Zhang C. Lifestyle interventions can reduce the risk of Barrett’s esophagus: a systematic review and meta-analysis of 62 studies involving 250,157 participants[J]. Cancer Med, 2021, 10(15): 5297-5320.
35. Karimian M, Salamati M, Azami M. The relationship between metabolic syndrome and increased risk of Barrett’s esophagus: an updated systematic review and meta-analysis[J]. BMC Gastroenterol, 2020, 20(1): 138.
36. Liu BD, Udemba SC, Saleh S, et al. Raloxifene increases the risk of gastroesophageal reflux disease, Barrett’s esophagus, and esophageal stricture in postmenopausal women with osteoporosis[J]. Neurogastroenterol Motil, 2023, 35(12): e14689.
37. Huang Y, Cai Y, Chen Y, et al. Cholelithiasis and cholecystectomy increase the risk of gastroesophageal reflux disease and Barrett’s esophagus[J]. Front Med (Lausanne), 2024, 11: 1420462.
38. Ma S, Tong Z, He Y, et al. Association between hiatal hernia and Barrett’s esophagus: an updated meta-analysis with trial sequential analysis[J]. Therap Adv Gastroenterol, 2024, 17: 17562848231219234.
39. Iwaya Y, Goda K, Kako S, et al. Association between endoscopic evidence of bile reflux and Barrett’s esophagus: a large-scale case-control study[J]. Dig Liver Dis, 2024, 56(4): 622-627.
40. Liu Q, Liu X, Gao M, et al. Investigation of causal associations between cerebral cortical structure and Barrett’s esophagus: insights from Mendelian randomization and meta-analysis[J]. J Thorac Dis, 2024, 16(12): 8582-8601.
41. Edelstein ZR, Bronner MP, Rosen SN, et al. Risk factors for Barrett’s esophagus among patients with gastroesophageal reflux disease: a community clinic-based case-control study[J]. Am J Gastroenterol, 2009, 104(4): 834-842.
42. Eusebi LH, Telese A, Cirota GG, et al. Systematic review with meta-analysis: risk factors for Barrett’s oesophagus in individuals with gastro-oesophageal reflux symptoms[J]. Aliment Pharmacol Ther, 2021, 53(9): 968-976.
43. Zhang J, Wu H, Wang R. Effect of nonsteroidal anti-inflammatory drugs on Barrett’s esophagus risk: a systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2021, 45(3): 101552.
44. Zhang X, Yang X, Zhang T, et al. Association of educational attainment with esophageal cancer, Barrett’s esophagus, and gastroesophageal reflux disease, and the mediating role of modifiable risk factors: a Mendelian randomization study[J]. Front Public Health, 2023, 11: 1022367.
45. Zhou J, Fang P, Liu Y, et al. Causal relationship between cheese intake and risk of gastroesophageal reflux disease and Barrett’s esophagus: findings from multivariable mendelian randomization and mediation analysis[J]. Eur J Nutr, 2024, 64(1): 49.
46. 中國醫療保健國際交流促進會胃食管反流病學分會. 中國胃食管反流病多學科診療共識 2022(一)[J]. 中華胃食管反流病電子雜志, 2022, 9(2): 51-86.
47. von Rahden BH, Stein HJ, Becker K, et al. Heterotopic gastric mucosa of the esophagus: literature-review and proposal of a clinicopathologic classification[J]. Am J Gastroenterol, 2004, 99(3): 543-551.
48. Chong VH, Jalihal A. Heterotopic gastric mucosal patch of the esophagus is associated with higher prevalence of laryngopharyngeal reflux symptoms[J]. Eur Arch Otorhinolaryngol, 2010, 267(11): 1793-1799.
49. Yu X, Wang J, Jin T, et al. Laryngopharyngeal symptoms and oesophageal disorder: the role of heterotopic gastric mucosa in upper oesophagus[J]. Clin Otolaryngol, 2023, 48(1): 32-38.
50. Chen X, Zhou S, Shi C, et al. Association of heterotopic gastric mucosa in the upper esophagus (HGMUE) with pharyngolaryngeal symptoms: a systematic review and meta-analysis[J]. Dig Dis Sci, 2024, 69(12): 4416-4429.
51. Romańczyk M, Budzyń K, Romańczyk T, et al. Heterotopic gastric mucosa in the proximal esophagus: prospective study and systematic review on relationships with endoscopic findings and clinical data[J]. Dysphagia, 2023, 38(2): 629-640.
52. 吳瑞暖, 劉朝暉. 食管胃黏膜異位病理診斷分型與臨床癥狀的關系[J]. 海南醫學, 2020, 10(11): 1377-1379.
53. Wang Z, Chen Y, Sun H, et al. Risk factors for symptoms in patients with heterotopic gastric mucosa in the upper esophagus[J]. Gastroenterol Res Pract, 2025, 2025: 7658517.
54. Bognár L, Vereczkei A, Papp A, et al. Gastroesophageal reflux disease might induce certain-supposedly adaptive-changes in the esophagus: a hypothesis[J]. Dig Dis Sci, 2018, 63(10): 2529-2535.
55. Iwaya Y, Shimamura Y, Goda K, et al. Clinical characteristics of young patients with early Barrett’s neoplasia[J]. World J Gastroenterol, 2019, 25(24): 3069-3078.
56. Quach DT, Pham QTT, Tran TLT, et al. Prevalence, clinical characteristics, and risk factors of Barrett esophagus in Vietnamese patients with upper gastrointestinal symptoms[J]. Medicine (Baltimore), 2020, 99(34): e21791.
57. Lechien JR, Saussez S, Muls V, et al. Laryngopharyngeal reflux: a state-of-the-art algorithm management for primary care physicians[J]. J Clin Med, 2020, 9(11): 3618.
58. Nason KS, Murphy T, Schindler J, et al. A cross-sectional analysis of the prevalence of Barrett esophagus in otolaryngology patients with laryngeal symptoms[J]. J Clin Gastroenterol, 2013, 47(9): 762-768.
59. Taylor JB, Rubenstein JH. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett’s esophagus[J]. Am J Gastroenterol, 2010, 105(8): 1729, 1730-1737, quiz 1738.
60. Eusebi LH, Telese A, Cirota GG, et al. Effect of gastro-esophageal reflux symptoms on the risk of Barrett’s esophagus: a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2022, 37(8): 1507-1516.
61. Borhan-Manesh F, Farnum JB. Incidence of heterotopic gastric mucosa in the upper oesophagus[J]. Gut, 1991, 32(9): 968-972.
62. 熊鑫, 何素玉, 徐菲, 等. 食管上段胃黏膜異位內鏡下合并癥的研究[J]. 中國內鏡雜志, 2021, 27(4): 1-6.
63. ASGE Standards of Practice Committee, Qumseya B, Sultan S, et al. ASGE guideline on screening and surveillance of Barrett’s esophagus[J]. Gastrointest Endosc, 2019, 90(3): 335-359.
64. Weusten BLAM, Bisschops R, Dinis-Ribeiro M, et al. Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline[J]. Endoscopy, 2023, 55(12): 1124-1146.
65. Khatri R, Patel J, Song J, et al. Esophageal inlet patch: association with Barrett’s esophagus[J]. Dig Dis Sci, 2023, 68(9): 3671-3678.
66. Frieling T, Kuhlbusch-Zicklam R, Weingardt C, et al. Clinical impact of esophageal function tests and argon plasma coagulation in heterotopic gastric mucosa of the esophagus and extraesophageal reflux symptoms - a prospective study[J]. Z Gastroenterol, 2015, 53(2): 101-107.
67. Rosztóczy A, Izbéki F, Németh IB, et al. Detailed esophageal function and morphological analysis shows high prevalence of gastroesophageal reflux disease and Barrett’s esophagus in patients with cervical inlet patch[J]. Dis Esophagus, 2012, 25(6): 498-504.
68. Korkut E, Bekta? M, Alkan M, et al. Esophageal motility and 24-h pH profiles of patients with heterotopic gastric mucosa in the cervical esophagus[J]. Eur J Intern Med, 2010, 21(1): 21-24.
69. Coenraad M, Masclee AA, Straathof JW, et al. Is Barrett’s esophagus characterized by more pronounced acid reflux than severe esophagitis?[J]. Am J Gastroenterol, 1998, 93(7): 1068-1072.
70. Iwakiri K, Sugiura T, Hayashi Y, et al. Esophageal motility in Japanese patients with Barrett’s esophagus[J]. J Gastroenterol, 2003, 38(11): 1036-1041.
71. Bazin C, Benezech A, Alessandrini M, et al. Esophageal motor disorders are a strong and independant associated factor of Barrett’s esophagus[J]. J Neurogastroenterol Motil, 2018, 24(2): 216-225.
72. Alonso O, Hernández D, Moreno E, et al. The real value of lower esophageal sphincter measurement for predicting acid gastroesophageal reflux or Barrett’s esophagus[J]. J Gastrointest Surg, 2005, 9(7): 973-979.
73. Fass R, Teramoto O, Kurin M, et al. Esophageal function abnormalities in patients with Barrett’s esophagus[J]. J Clin Gastroenterol, 2020, 54(6): 485-492.
74. Gutschow CA, Bludau M, Vallb?hmer D, et al. NERD, GERD, and Barrett’s esophagus: role of acid and non-acid reflux revisited with combined pH-impedance monitoring[J]. Dig Dis Sci, 2008, 53(12): 3076-3081.
75. Tian Y, Zhang W, Zhang T, et al. Analysis of the correlation between dynamic characteristics and symptoms of gastroesophageal reflux disease[J]. Surg Laparosc Endosc Percutan Tech, 2024, 34(3): 268-274.
76. Meneghetti AT, Tedesco P, Damani T, et al. Esophageal mucosal damage may promote dysmotility and worsen esophageal acid exposure[J]. J Gastrointest Surg, 2005, 9(9): 1313-1317.
77. Cho YK. Length of the Barrett’s esophagus is proportional to the abnormality of esophageal motility and anti-reflux barrier[J]. J Neurogastroenterol Motil, 2023, 29(1): 5-6.
78. Falc?o A, Nasi A, Brand?o J, et al. What is the real impairment on esophageal motility in patients with gastroesophageal reflux disease?[J]. Arq Gastroenterol, 2013, 50(2): 111-116.
79. Shibli F, Fass OZ, Teramoto OM, et al. Esophageal hypocontractile disorders and hiatal hernia size are predictors for long segment Barrett’s esophagus[J]. J Neurogastroenterol Motil, 2023, 29(1): 31-37.
80. Oberg S, DeMeester TR, Peters JH, et al. The extent of Barrett’s esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure[J]. J Thorac Cardiovasc Surg, 1999, 117(3): 572-580.
81. Lidums I, Holloway R. Motility abnormalities in the columnar-lined esophagus[J]. Gastroenterol Clin North Am, 1997, 26(3): 519-531.
82. Yadlapati R, Triggs J, Quader F, et al. Reduced esophageal contractility is associated with dysplasia progression in Barrett’s esophagus: a multicenter cohort study[J]. Dig Dis Sci, 2020, 65(12): 3631-3638.
83. Mason RJ, Bremner CC. Motility differences between long-segment and short-segment Barrett’s esophagus[J]. Am J Surg, 1993, 165(6): 686-689.
84. Falc?o AM, Nasi A, Szachnowicz S, et al. Does the nissen fundoplication procedure improve esophageal dysmotility in patients with Barrett’s esophagus[J]. Rev Col Bras Cir, 2020, 47: e20202637.
85. Philonenko S, Roman S, Zerbib F, et al. Jackhammer esophagus: clinical presentation, manometric diagnosis, and therapeutic results-Results from a multicenter French cohort[J]. Neurogastroenterol Motil, 2020, 32(11): e13918.
86. Dao HV, Hoang LB, Luu MT, et al. High prevalence of esophagitis in patients with severe ineffective esophageal motility: need for a new diagnostic cutoff[J]. Ann Gastroenterol, 2022, 35(5): 483-488.
87. Guo JP, Gilman PB, Thomas RM, et al. Barrett’s esophagus and achalasia[J]. J Clin Gastroenterol, 2002, 34(4): 439-443.
88. Leeuwenburgh I, Scholten P, Caljé TJ, et al. Barrett’s esophagus and esophageal adenocarcinoma are common after treatment for achalasia[J]. Dig Dis Sci, 2012, 58(1): 244-252.
89. Yadlapati R, Kahrilas PJ, Fox MR, et al. Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0?[J]. Neurogastroenterol Motil, 2021, 33(1): e14058.
90. Hamilton JW, Thune RG, Morrissey JF. Symptomatic ectopic gastric epithelium of the cervical esophagus. Demonstration of acid production with Congo red[J]. Dig Dis Sci, 1986, 31(4): 337-342.
91. Loughney T, Maydonovitch CL, Wong RK. Esophageal manometry and ambulatory 24-hour pH monitoring in patients with short and long segment Barrett’s esophagus[J]. Am J Gastroenterol, 1998, 93(6): 916-919.
92. Csendes A, Smok G, Quiroz J, et al. Clinical, endoscopic, and functional studies in 408 patients with Barrett’s esophagus, compared to 174 cases of intestinal metaplasia of the cardia[J]. Am J Gastroenterol, 2002, 97(3): 554-560.
93. Gillen P, Keeling P, Byrne PJ, et al. Barrett’s oesophagus: pH profile[J]. Br J Surg, 1987, 74(9): 774-776.
94. Shapiro M, Green C, Faybush EM, et al. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups[J]. Aliment Pharmacol Ther, 2006, 23(2): 321-329.
95. Dickman R, Bautista JM, Wong WM, et al. Comparison of esophageal acid exposure distribution along the esophagus among the different gastroesophageal reflux disease (GERD) groups[J]. Am J Gastroenterol, 2006, 101(11): 2463-2469.
96. Savarino E, Zentilin P, Frazzoni M, et al. Characteristics of gastro-esophageal reflux episodes in Barrett’s esophagus, erosive esophagitis and healthy volunteers[J]. Neurogastroenterol Motil, 2010, 22(10): 1061-e280.
97. Basnayake C, Geeraerts A, Pauwels A, et al. Systematic review: duodenogastroesophageal (biliary) reflux prevalence, symptoms, oesophageal lesions and treatment[J]. Aliment Pharmacol Ther, 2021, 54(6): 755-778.
98. Stein HJ, Kauer WK, Feussner H, et al. Bile reflux in benign and malignant Barrett’s esophagus: effect of medical acid suppression and nissen fundoplication[J]. J Gastrointest Surg, 1998, 2(4): 333-341.
99. Ciocalteu A, Popa P, Ionescu M, et al. Issues and controversies in esophageal inlet patch[J]. World J Gastroenterol, 2019, 25(30): 4061-4073.
100. Yamada T, Tsuji A, Onoue S, et al. Acid suppressive therapy improved symptoms due to circumferential cervical inlet patch with proton pumps (H⁺/K⁺-ATPase)[J]. World J Clin Cases, 2017, 5(11): 403-406.
101. Sharma P, Shaheen NJ, Katzka D, et al. AGA clinical practice update on endoscopic treatment of Barrett’s esophagus with dysplasia and/or early cancer: expert review[J]. Gastroenterology, 2020, 158(3): 760-769.
102. Chen Y, Sun C, Wu Y, et al. Do proton pump inhibitors prevent Barrett’s esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis[J]. J Cancer Res Clin Oncol, 2021, 147(9): 2681-2691.
103. Zhuang Q, Chen S, Zhou X, et al. Comparative efficacy of P-CAB vs proton pump inhibitors for grade C/D esophagitis: a systematic review and network meta-analysis[J]. Am J Gastroenterol, 2024, 119(5): 803-813.
104. Neumann WL, Luján GM, Genta RM et al. Gastric heterotopia in the proximal oesophagus (“inlet patch”): association with adenocarcinomas arising in Barrett mucosa[J]. Dig Liver Dis, 2012, 44(4): 292-206.
105. Alagozlu H, Simsek Z, Unal S, et al. Is there an association between Helicobacter pylori in the inlet patch and globus sensation?[J]. World J Gastroenterol, 2010, 16(1): 42-47.
106. Riddiough GE, Hornby ST, Asadi K, et al. Gastric adenocarinoma of the upper oesophagus: a literature review and case report[J]. Int J Surg Case Rep, 2017, 30(14): 205-214.
107. Orosey M, Amin M, Cappell MS. A 14-year study of 398 esophageal adenocarcinomas diagnosed among 156, 256 EGDs performed at two large hospitals: an inlet patch is proposed as a significant risk factor for proximal esophageal adenocarcinoma[J]. Dig Dis Sci, 2018, 63(2): 452-465.
108. Chong VH. Clinical significance of heterotopic gastric mucosal patch of the proximal esophagus[J]. World J Gastroenterol, 2013, 19(3): 331-338.
109. Latos W, Sieroń-Sto?tny K, Kawczyk-Krupka A, et al. Clinical evaluation of twenty cases of heterotopic gastric mucosa of upper esophagus during five-year observation, using gastroscopy in combination with histopathological and microbiological analysis of biopsies[J]. Contemp Oncol, 2013, 17(2): 171-175.
110. 赫捷, 陳萬青, 李兆申, 等. 中國食管癌篩查與早診早治指南(2022, 北京)[J]. 中華腫瘤雜志, 2022, 44(6): 491-522.
111. Uhlenhopp DJ, Then EO, Sunkara T, et al. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors[J]. Clin J Gastroenterol, 2020, 13(6): 1010-1021.
112. Harrison M, Allen JE, Gorrepati VS, et al. Management of Barrett’s esophagus with low-grade dysplasia[J]. Dis Esophagus, 2018, 31(4): 101-109.
113. Fabian T, Leung A. Epidemiology of Barrett’s esophagus and esophageal carcinoma[J]. Surg Clin North Am, 2021, 101(3): 381-389.

Previous Article
Application progress of artificial intelligence in exercise management for patients with chronic kidney disease
Next Article
Research progress on osteoporotic acetabular fractures in the elderly

West China Medical Journal

Research progress on heterotopic gastric mucosa in the esophagus

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content